Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
The AMR Action Fund is a venture capital fund formed through collaborations with the International Federation of Pharmaceutical Manufacturers and Associations, the World Health Organization, the European Investment Bank, and the Wellcome Trust. Based globally, the fund focuses on addressing antimicrobial resistance (AMR) by investing in innovative therapeutic solutions. It currently supports 11 portfolio companies and aims to launch two to four new antimicrobials by 2030.
This fund invests in small and mid-size biotechnology companies developing treatments for priority pathogens identified by the World Health Organization and the Centers for Disease Control and Prevention. The AMR Action Fund targets clinical-stage companies working on both traditional small-molecule compounds and innovative modalities like bacteriophages and antibody treatments. Additionally, it advocates for market reforms to enhance the value of lifesaving drugs.
Notable portfolio companies include BioVersys, focused on therapies for drug-resistant pathogens; BiomX, advancing phage therapies; Venatorx Pharmaceuticals, developing a beta-lactam/beta-lactamase inhibitor; Vedanta Biosciences, working on drugs for Clostridioides difficile infections; and Pattern Bioscience, developing a diagnostics platform for bacterial pathogens.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.